ReviewGastrointestinal endoscopy2016
Gastrointestinal traits: individualizing therapy for obesity with drugs and devices.
Review in Gastrointestinal endoscopy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 4 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Association of long-term weight management pharmacotherapy with multiple health outcomes: an umbrella review and evidence map.International journal of obesity (2005) · 2025Pooled it
- Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Obese with or without Diabetes: A Systematic Review and Meta-Analysis.International journal of clinical practice · 2022Pooled it
- Changes in Time of Gastric Emptying After Surgical and Endoscopic Bariatrics and Weight Loss: A Systematic Review and Meta-Analysis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2020Pooled it
- Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.JAMA · 2016 · on this mapPooled it
- Broader Validation of New Zealand Eating Behavior Questionnaire as Clinical Assessment Tool to Identify Actionable Eating Behavior Traits.Nutrients · 2025Article
- Pain-free oral delivery of biologic drugs using intestinal peristalsis-actuated microneedle robots.Science advances · 2024Article
- Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review.Therapeutic advances in chronic disease · 2022Review
- Precision Medicine for Obesity.Digestive disease interventions · 2021Article
- Precision Medicine and Obesity.Gastroenterology clinics of North America · 2021 · on this mapReview
- A Role for GLP-1 in Treating Hyperphagia and Obesity.Endocrinology · 2020Review
- Insights on Obesity in Children and Adults: Individualizing Management.Trends in endocrinology and metabolism: TEM · 2019Review
- Accelerated gastric emptying is associated with improved aspiration efficiency in obesity.BMJ open gastroenterology · 2019Article
- Endoscopic Treatments for Obesity.Current treatment options in gastroenterology · 2017Review
- Amylin receptor activation in the ventral tegmental area reduces motivated ingestive behavior.Neuropharmacology · 2017Article
- A working paradigm for the treatment of obesity in gastrointestinal practice.Techniques in gastrointestinal endoscopy · 2017Article
- Precision Bariatrics: Toward a New Paradigm of Personalized Devices in Obesity Therapeutics.Obesity surgery · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
BACKGROUND AND
aimsThe aims of this article were to review the discrepancy between numbers of people requiring weight loss treatment and results and to assess the potential effects of pharmacologic treatments (recently approved for obesity) and endoscopically deployed devices on quantitative GI traits in development for obesity treatment.
methodsWe conducted a review of relevant literature to achieve our objectives.
resultsThe 2013 guidelines increased the number of adults recommended for weight loss treatment by 20.9% (116.0 million to 140.2 million). There is an imbalance between efficacy and costs of commercial weight loss programs and drug therapy (average weight loss about 5 kg). The number of bariatric procedures performed in the United States has doubled in the past decade. The efficacy of bariatric surgery is attributed to reduction in the volume of the stomach, nutrient malabsorption with some types of surgery, increased postprandial incretin responses, and activation of farnesoid X receptor mechanisms. These GI and behavioral traits identify sub-phenotypes of obesity, based on recent research.
conclusionsThe mechanisms or traits targeted by drug and device treatments include centrally mediated alterations of appetite or satiation, diversion of nutrients, and alteration of stomach capacity, gastric emptying, or incretin hormones. Future treatment may be individualized based on quantitative GI and behavioral traits measured in obese patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.